Future Price to Earnings: Prenetics Global (PRE)

Historical price action helps assess the effectiveness of the Prenetics Global (PRE) strategy, where the current indicator stands at 0.00. Prenetics Global (PRE) generates revenue through the sale of CircleDNA genetic tests and diagnostic services for clinics and individuals. The technical infrastructure relies on updated DNA sequencers and automated sample sorting, providing laboratories with excellent operational efficiency and stable capacity utilization.

PRE - prenetics.com Market Cap to Projected Earnings over the range 04/28/2023 - 11/12/2026

Prenetics Global Ltd - analytical breakdowns and key metrics (PRE)

- current price and projected stock value:

Stock Quotes Prenetics Global|PRE - Average Forecast Price

- company stock exchange capitalization indicators:

Market Value Prenetics Global Limited|PRE - Company Buyout Price

- balance sheet equity data:

Book Value per Share Prenetics|PRE - Book Valuation of Business|Market Value to Book Value Ratio prenetics.com|PRE - Company Total Asset Base

- debt and liquidity details:

- earnings and market ratios statistics:

PRE - Company Net Income|Future Profit Prenetics Global|PRE - Market Price to Net Income Ratio|Forward P/E Multiple Prenetics Global|PRE - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Prenetics Global Limited|PRE - Operating profit before deduction of amortization|Earnings per share for the last twelve months Prenetics|PRE - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months prenetics.com|PRE - Earnings per share increase in current year|Earnings growth forecast for next year Prenetics Global

Fundamental valuation:Prenetics

Prenetics Global revenues depend on scaling CircleDNA test sales across Asian and European markets. By analyzing the issuer's forward P/E, an investor assesses the current share price relative to expected earnings. This chart smooths out market noise by connecting equilibrium points to identify the long-term valuation trend. This approach prevents the purchase of an overvalued asset at the cycle peak. This indicator determines the fundamental attractiveness of the securities within the genomics sector.

Competitors of Prenetics Global (PRE)